Global Malignant Mesothelioma Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2024

  • receipt Report ID : 157397
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 136
  • list Pharmaceuticals and Healthcare

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).

Scope of the Report:

This report studies the Malignant Mesothelioma market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Malignant Mesothelioma market by product type and applications/end industries.

Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of mesothelioma drugs by governments to ensure availability in hospital pharmacies and oncology centers.

The global Malignant Mesothelioma market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Malignant Mesothelioma.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

AstraZeneca

Bristol-Myers Squibb

Roche

Merck

Novartis

Pfizer

Sanofi

Eli Lilly

Teva Pharmaceuticals

Boehringer Ingelheim GmbH

Mylan

Fresenius Kabi

Sun Pharmaceuticals

Corden Pharma

Concordia International

Kyowa Hakko Kirin

Polaris Pharmaceuticals

MolMed

Ono Pharmaceutical

Nichi-Iko Pharmaceutical

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Oral

Parenteral

Market Segment by Applications, can be divided into

Hospital Pharmacies

Retail Pharmacies

Oncology Centers

Other

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Malignant Mesothelioma Market Overview

1.1 Product Overview and Scope of Malignant Mesothelioma

1.2 Classification of Malignant Mesothelioma by Types

1.2.1 Global Malignant Mesothelioma Revenue Comparison by Types (2017-2023)

1.2.2 Global Malignant Mesothelioma Revenue Market Share by Types in 2017

1.2.3 Oral

1.2.4 Parenteral

1.3 Global Malignant Mesothelioma Market by Application

1.3.1 Global Malignant Mesothelioma Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Oncology Centers

1.3.5 Other

1.4 Global Malignant Mesothelioma Market by Regions

1.4.1 Global Malignant Mesothelioma Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Malignant Mesothelioma Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Malignant Mesothelioma Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Malignant Mesothelioma Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Malignant Mesothelioma Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Malignant Mesothelioma Status and Prospect (2013-2023)

1.5 Global Market Size of Malignant Mesothelioma (2013-2023)

2 Manufacturers Profiles

2.1 AstraZeneca

2.1.1 Business Overview

2.1.2 Malignant Mesothelioma Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 AstraZeneca Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.2 Bristol-Myers Squibb

2.2.1 Business Overview

2.2.2 Malignant Mesothelioma Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Bristol-Myers Squibb Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.3 Roche

2.3.1 Business Overview

2.3.2 Malignant Mesothelioma Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Roche Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.4 Merck

2.4.1 Business Overview

2.4.2 Malignant Mesothelioma Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Merck Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.5 Novartis

2.5.1 Business Overview

2.5.2 Malignant Mesothelioma Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Novartis Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.6 Pfizer

2.6.1 Business Overview

2.6.2 Malignant Mesothelioma Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Pfizer Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.7 Sanofi

2.7.1 Business Overview

2.7.2 Malignant Mesothelioma Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Sanofi Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.8 Eli Lilly

2.8.1 Business Overview

2.8.2 Malignant Mesothelioma Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Eli Lilly Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.9 Teva Pharmaceuticals

2.9.1 Business Overview

2.9.2 Malignant Mesothelioma Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Teva Pharmaceuticals Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.10 Boehringer Ingelheim GmbH

2.10.1 Business Overview

2.10.2 Malignant Mesothelioma Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.11 Mylan

2.11.1 Business Overview

2.11.2 Malignant Mesothelioma Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Mylan Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.12 Fresenius Kabi

2.12.1 Business Overview

2.12.2 Malignant Mesothelioma Type and Applications

2.12.2.1 Product A

2.12.2.2 Product B

2.12.3 Fresenius Kabi Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.13 Sun Pharmaceuticals

2.13.1 Business Overview

2.13.2 Malignant Mesothelioma Type and Applications

2.13.2.1 Product A

2.13.2.2 Product B

2.13.3 Sun Pharmaceuticals Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.14 Corden Pharma

2.14.1 Business Overview

2.14.2 Malignant Mesothelioma Type and Applications

2.14.2.1 Product A

2.14.2.2 Product B

2.14.3 Corden Pharma Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.15 Concordia International

2.15.1 Business Overview

2.15.2 Malignant Mesothelioma Type and Applications

2.15.2.1 Product A

2.15.2.2 Product B

2.15.3 Concordia International Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.16 Kyowa Hakko Kirin

2.16.1 Business Overview

2.16.2 Malignant Mesothelioma Type and Applications

2.16.2.1 Product A

2.16.2.2 Product B

2.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.17 Polaris Pharmaceuticals

2.17.1 Business Overview

2.17.2 Malignant Mesothelioma Type and Applications

2.17.2.1 Product A

2.17.2.2 Product B

2.17.3 Polaris Pharmaceuticals Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.18 MolMed

2.18.1 Business Overview

2.18.2 Malignant Mesothelioma Type and Applications

2.18.2.1 Product A

2.18.2.2 Product B

2.18.3 MolMed Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.19 Ono Pharmaceutical

2.19.1 Business Overview

2.19.2 Malignant Mesothelioma Type and Applications

2.19.2.1 Product A

2.19.2.2 Product B

2.19.3 Ono Pharmaceutical Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

2.20 Nichi-Iko Pharmaceutical

2.20.1 Business Overview

2.20.2 Malignant Mesothelioma Type and Applications

2.20.2.1 Product A

2.20.2.2 Product B

2.20.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Revenue, Gross Margin and Market Share (2016-2017)

3 Global Malignant Mesothelioma Market Competition, by Players

3.1 Global Malignant Mesothelioma Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Malignant Mesothelioma Players Market Share

3.2.2 Top 10 Malignant Mesothelioma Players Market Share

3.3 Market Competition Trend

4 Global Malignant Mesothelioma Market Size by Regions

4.1 Global Malignant Mesothelioma Revenue and Market Share by Regions

4.2 North America Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

4.3 Europe Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

4.5 South America Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

5 North America Malignant Mesothelioma Revenue by Countries

5.1 North America Malignant Mesothelioma Revenue by Countries (2013-2018)

5.2 USA Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

5.3 Canada Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

5.4 Mexico Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

6 Europe Malignant Mesothelioma Revenue by Countries

6.1 Europe Malignant Mesothelioma Revenue by Countries (2013-2018)

6.2 Germany Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

6.3 UK Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

6.4 France Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

6.5 Russia Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

6.6 Italy Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Malignant Mesothelioma Revenue by Countries

7.1 Asia-Pacific Malignant Mesothelioma Revenue by Countries (2013-2018)

7.2 China Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

7.3 Japan Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

7.4 Korea Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

7.5 India Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

8 South America Malignant Mesothelioma Revenue by Countries

8.1 South America Malignant Mesothelioma Revenue by Countries (2013-2018)

8.2 Brazil Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

8.3 Argentina Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

8.4 Colombia Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Malignant Mesothelioma by Countries

9.1 Middle East and Africa Malignant Mesothelioma Revenue by Countries (2013-2018)

9.2 Saudi Arabia Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

9.3 UAE Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

9.4 Egypt Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

9.5 Nigeria Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

9.6 South Africa Malignant Mesothelioma Revenue and Growth Rate (2013-2018)

10 Global Malignant Mesothelioma Market Segment by Type

10.1 Global Malignant Mesothelioma Revenue and Market Share by Type (2013-2018)

10.2 Global Malignant Mesothelioma Market Forecast by Type (2018-2023)

10.3 Oral Revenue Growth Rate (2013-2023)

10.4 Parenteral Revenue Growth Rate (2013-2023)

11 Global Malignant Mesothelioma Market Segment by Application

11.1 Global Malignant Mesothelioma Revenue Market Share by Application (2013-2018)

11.2 Malignant Mesothelioma Market Forecast by Application (2018-2023)

11.3 Hospital Pharmacies Revenue Growth (2013-2018)

11.4 Retail Pharmacies Revenue Growth (2013-2018)

11.5 Oncology Centers Revenue Growth (2013-2018)

11.6 Other Revenue Growth (2013-2018)

12 Global Malignant Mesothelioma Market Size Forecast (2018-2023)

12.1 Global Malignant Mesothelioma Market Size Forecast (2018-2023)

12.2 Global Malignant Mesothelioma Market Forecast by Regions (2018-2023)

12.3 North America Malignant Mesothelioma Revenue Market Forecast (2018-2023)

12.4 Europe Malignant Mesothelioma Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Malignant Mesothelioma Revenue Market Forecast (2018-2023)

12.6 South America Malignant Mesothelioma Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Malignant Mesothelioma Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Malignant Mesothelioma Picture

Table Product Specifications of Malignant Mesothelioma

Table Global Malignant Mesothelioma and Revenue (Million USD) Market Split by P

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery